Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis

PURPOSE: There is currently a lack of studies investigating long-term prognosis and the necessity of further rituximab (RTX) consolidation treatment for minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS). The aim of this study was to evaluate the efficacy of RTX for these dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Li, Wang, Weiming, Wu, YiFan, Xie, JingYuan, Li, Xiao, Pan, XiaoXia, Zhang, Wen, Xu, Jing, Cai, YiKai, Ren, Hong, Chen, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121273/
https://www.ncbi.nlm.nih.gov/pubmed/34007154
http://dx.doi.org/10.2147/DDDT.S302257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121273/
https://www.ncbi.nlm.nih.gov/pubmed/34007154
http://dx.doi.org/10.2147/DDDT.S302257

Ejemplares similares